As more patients with oncogene-driven non-small-cell lung cancer are treated with targeted therapies, they are joining forces online to form groups that provide support, education and advocacy focused on specific oncogenes. Herein, we discuss how the involvement of these groups in patient-partnered research can benefit both patients and lung cancer research.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sequist, L. V. & Neal, J. W. Personalized, genotype-directed therapy for advanced non-small cell lung cancer. UpToDate https://www.uptodate.com/contents/personalized-genotype-directed-therapy-for-advanced-non-small-cell-lung-cancer (2019).
Freeman-Daily, J. ROS1+ cancer patients partner to increase research. Updates and Insights Blog www.cancer.gov/about-nci/organization/ccg/blog/2017/ros1-patient-driven-research (2017).
Scheffler, M. “[The ROS1ders] definitely know more about the disease, about the genetics of ROS1, about the treatments of ROS1, than 99.5% of my colleagues in Germany.” Excerpt from panel discussion “How to deal with diversity early on: Personalised early clinical trials” at the 2019 annual meeting of European Society for Clinical Oncology, Barcelona, Spain (2019).
@JackWestMD. “Time to highlight that we are now in an era when pts w/rare cancers are increasingly likely to know more than docs, even very good ones, about their dzs. This @ros1cancer page on Drugs to Treat ROS1+ NSCLC deserves its place at top of Google search: bit.ly/ROS1Rxs #LCSM.” Twitter https://twitter.com/JackWestMD/status/989287575469805568 (2018).
Camidge, D. R. & Freeman-Daily, J. The ROS1ders Interview Dr Ross Camidge, produced by GO2 Foundation for Lung Cancer. YouTube, www.youtube.com/watch?v=Hs3a9gjqzIA (2019).
Freeman-Daily, J. et al. “The Global ROS1 Initiative: a patient-researcher partnership generating open-source, oncogene-driven cancer models and data.” Poster presentation at the 2018 annual meeting of the American Association of Cancer Research, Chicago, IL (2018).
Neel, D. S. et al. Differential subcellular localization regulates oncogenic signaling by ROS1 kinase fusion proteins. Cancer Res. 79, 546–556 (2019).
McCoach, C. E. et al. Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer. Clin. Cancer Res. 24, 3334–3347 (2018).
Davies, K. D. et al. Comparison of molecular testing modalities for detection of ROS1 rearrangements in a cohort of positive patient samples. J. Thorac. Oncol. 13, 1474–1482 (2018).
Patil, T. et al. The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. J. Thorac. Oncol. 13, 1717–1726 (2018).
Elkins, I. et al. Project PRIORITY: A patient-founded and patient-driven research partnership to gather real-world data on EGFR-positive lung cancer [abstr MA16.01]. Presented at the International Association for the Study of Lung Cancer (IASLC) 2019 World Conference on Lung Cancer (WCLC 2019), Barcelona, Spain (2019).
LUNGevity Foundation. Partner Awards: ALK-positive lung cancer transformational research awards. lungevity.org https://lungevity.org/research/translational-science-research-grant-programs/funded-projects/partner-awards (2018).
Acknowledgements
The authors thank the members of The ROS1ders, our research partners (the GO2 Foundation for Lung Cancer, the Addario Lung Cancer Medical Institute, Champions Oncology and LUNGevity Foundation); R. Doebele and R. Camidge of the University of Colorado; C. Lovly of Vanderbilt University; A. van der Wekken of the University Medical Center, Groningen; L. Drayer and M. Smelt of the Hanze University of Applied Science, Groningen; the pharmaceutical companies who make treatments for ROS1-positive cancers; and the network of patients, caregivers, advocates, volunteers, researchers, clinicians, non-profit organizations and donors who make our work possible.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Related links
ALK Positive: https://www.alkpositive.org/
ALK Positive on Facebook: https://www.facebook.com/groups/ALKPositive/
EGFR Resisters Lung Cancer Patient Group on Facebook: https://www.facebook.com/groups/EGFRResisters/
EGFR Resisters: https://egfrcancer.org/
Exon 20 group: https://exon20group.org/
The EGFR Exon 20 Support Group on Facebook: https://www.facebook.com/groups/136311127056022/
The ROS1ders Patient Group on Facebook “ROS1 Positive (ROS1+) Cancer”: https://www.facebook.com/groups/ROS1cancer/
The ROS1ders website: https://ros1cancer.com/
Rights and permissions
About this article
Cite this article
Hennink, M., Vandeweyer, G., Freeman-Daily, J. et al. The roles of patient groups in fostering cancer research. Nat Rev Clin Oncol 17, 65–66 (2020). https://doi.org/10.1038/s41571-019-0314-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-019-0314-1
